Can montelukast (Singulair) cause depression? Learn what the research and FDA warnings say, and when to talk to your doctor.
Jump to a section
Montelukast is a leukotriene receptor antagonist prescribed for asthma and allergic rhinitis, and it now carries an FDA boxed warning for neuropsychiatric side effects, including depression. This article covers what the evidence actually shows, what the FDA warning means, and when new mood symptoms warrant a conversation with your doctor.
Key Takeaways on Montelukast and Depression
- The FDA added a boxed warning to montelukast for neuropsychiatric events, including depression and suicidal thoughts, based on post-marketing reports.
- Not everyone who takes montelukast experiences mood changes — the warning reflects a documented risk, not a guaranteed outcome.
- New or worsening depressive symptoms after starting montelukast should be reported to a prescriber, not dismissed as unrelated — a medication management specialist can help evaluate the connection.
- Stopping montelukast should be done under medical guidance, not abruptly on your own.
What Is Montelukast?
Montelukast (brand name Singulair) reduces airway inflammation by blocking leukotrienes, chemicals involved in asthma and allergic reactions. It's commonly prescribed as a daily maintenance medication rather than a rescue treatment for acute symptoms.
The FDA Warning on Neuropsychiatric Effects
The FDA has required a boxed warning — its strongest safety label — on montelukast specifically for neuropsychiatric events, including depression, agitation, sleep disturbances, and in rare cases, suicidal thoughts or actions. This warning followed years of post-marketing reports and led the FDA to recommend montelukast be reserved for patients who haven't responded well to other allergy or asthma treatments.
What the Research and Reports Show
The mechanism behind montelukast's neuropsychiatric effects isn't fully established, but the pattern of reports was consistent enough for regulatory action. It's worth noting these are relatively uncommon events against the large number of people who take montelukast without any mood-related side effects — the warning reflects a real but not universal risk.
What to Do If You Notice Mood Changes
- Don't dismiss new symptoms — new sadness, irritability, or anxiety after starting montelukast is worth reporting, even if it seems unrelated.
- Don't stop abruptly on your own — talk to your prescriber about tapering or switching, especially if it's controlling asthma symptoms.
- Seek immediate help for severe symptoms — thoughts of self-harm should be treated as an emergency regardless of suspected cause.
- Track the timeline — noting when mood symptoms started relative to the medication helps your doctor assess the connection.
When Mood Symptoms Need Broader Support
Whether or not montelukast is the cause, depression that's new or worsening deserves real evaluation and support (our guide on recognizing when depression needs professional evaluation covers this in more depth) — and for people managing both a mental health condition and substance use, treating them separately rarely works. Lantana Recovery's dual diagnosis program treats co-occurring mental health and substance use conditions together, recognizing that depression and addiction frequently interact. If you're managing depression alongside substance use, our outpatient and PHP programs address both, alongside individual therapy to work through the underlying mood symptoms directly.
FAQ: Montelukast and Depression
Does everyone who takes montelukast experience depression?
Should I stop taking montelukast if I feel depressed?
Are children at higher risk for these side effects?
Bottom Line
Montelukast carries a real, FDA-flagged risk of neuropsychiatric side effects including depression, though most people don't experience it. New mood symptoms after starting the medication are worth reporting promptly — and if depression and substance use are both part of the picture, integrated treatment addresses them together rather than in isolation.
Sources
- FDA — Boxed Warning update for montelukast (Singulair) on neuropsychiatric eventshttps://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-stronger-warning-about-risk-neuropsychiatric-events-asthma-and-allergy-drug
- DailyMed (NIH) — Montelukast prescribing informationhttps://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f4bfa07-4cae-4a15-91ba-1f6c9f0dc86d
Reviewed by
Warren PhillipsCo-Founder, LMSW · Editorial Reviewer
Warren Phillips is a Co-Founder of Lantana Recovery and a Licensed Master Social Worker (LMSW) specializing in substance abuse and mental health treatment. He previously worked in various capacities at Turnbridge Addiction Treatment and Clearpoint Recovery Center before co-founding Lantana Recovery. Warren's clinical approach draws on a strengths-based perspective, Twelve Step philosophies, Cognitive Behavioral Therapy, and Motivational Interviewing. He brings both personal and professional experience to his work — as a person in long-term recovery from alcohol and illicit substances, he has used that experience to help shape Lantana's treatment programming. Warren grew up in Memphis, TN and St. Louis, MO, attended college in Mississippi, and lived in California and Connecticut before relocating to Charleston. He now lives in Mount Pleasant with his wife, Angela, and their two young children, Hall and Sam.
Written by the Lantana Recovery Editorial Team and reviewed for clinical accuracy before publication.
